Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT02134574
Recruiting Observational

Prospective Cohort With Hemopathy in Languedoc-Roussillon

NCT02134574 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Montpellier
Phase
Observational
Started
2014-02
Last updated
2026-06-22

Condition(s) studied

Hematologic Malignancy

Investigational drug(s) / intervention(s)

hematologic malignancy

hematologic malignancy: hematologic malignancy with a sampling of blood

Study summary

Prospective Cohort Study of clinical and laboratory data of patients with hemopathy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion criteria: * Age over 18 * Consultant or hospitalized patient for suspected malignant hemopathy and justifying further exploration or patient with a diagnosis of malignant hemopathy less than 6 months old at the time of signing the consent * Having signed an informed consent * Affiliated with a social security scheme Exclusion criteria: * Minor or major protected * Patients who have received treatment for hematological pathology

Primary outcome measure(s)

  • Survival with 2 years — 2 years
    Prospective Cohort Study of clinical and biological data Analysis Biological, clinical and questionnaire EORTC\_QLQ-C30

Trial sites (1)

FacilityCityRegionStatus
Hematology department - UHMontpellier Saint éloi Montpellier France Recruiting

More University Hospital, Montpellier trials in France

Genomic Study of Cutis Tricolor Recruiting
Pre-analytical Processing of Human Samples for Microbiota Analysis Quality Starting soon
Glycosylation Analysis of Lupus Anti-DNA Antibodies (GALA) Recruiting
National Cohort of Subjects at Risk of Developing Rheumatoid Arthritis Recruiting
Strengthening, Guidance, Health, Empowerment Starting soon

Other trials for the same condition

Individualized First Maintenance Doses of Voriconazole Through a Multiparametric Algorithm Starting soon
Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO) Recruiting
Identifying Cellular and Molecular Determinants of Efficacy and Resistance in Patients Undergoing CAR-T Therapy Recruiting
Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation Recruiting
Early Assessment of Cardiac Function After Treatment With CAR-T Cells Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02134574 on ClinicalTrials.gov ↗ ← All trials in France